CDKN2A and glioblastoma: Multiple research teams have analyzed CDKN2A as an independent predictor of poor survival in both LGG and GBM (Lassaletta et al., 2017; Aoki et al., 2018; Shirahata et al., 2018; Appay et al., 2019).